Analysis Numerous independent directors of companies listed on the Shanghai and Shenzhen stock exchanges have resigned after the conclusion of the Kangmei Pharmaceutical trial, which found the health care company guilty of fabricating its financial statements. The court also ruled that Kangmei’s executives and board members are also liable and must compensate investors. The verdicts…